AbbVie Raises Guidance Based On Humira Patent Umbrella
This article was originally published in Scrip
Executive Summary
Analyst buzz about the AbbVie Inc. third quarter earnings call Oct. 30 centered on its strongly optimistic sales guidance through 2020, based on its belief in a suite of intellectual property that it says will protect top-seller Humira from US biosimilar competition until 2022 or later.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.